Moderna (NASDAQ:MRNA) Trading Down 3.9%

Moderna, Inc. (NASDAQ:MRNAGet Free Report)’s stock price was down 3.9% on Tuesday . The stock traded as low as $132.30 and last traded at $132.48. Approximately 1,055,980 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 4,160,952 shares. The stock had previously closed at $137.90.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Canaccord Genuity Group increased their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research note on Friday, May 3rd. Oppenheimer increased their price objective on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. HSBC restated a “reduce” rating and set a $86.00 price objective (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Monday, June 3rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $129.02.

Read Our Latest Report on MRNA

Moderna Stock Performance

The stock has a fifty day moving average of $129.61 and a 200 day moving average of $109.00. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNAGet Free Report) last announced its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s revenue was down 91.0% compared to the same quarter last year. During the same period last year, the firm posted $0.19 EPS. Research analysts anticipate that Moderna, Inc. will post -7.46 EPS for the current year.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,296 shares of Moderna stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $210,561.12. Following the sale, the insider now owns 10,623 shares of the company’s stock, valued at approximately $1,725,918.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $105.02, for a total value of $1,575,300.00. Following the completion of the transaction, the president now owns 1,486,241 shares in the company, valued at $156,085,029.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Shannon Thyme Klinger sold 1,296 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $210,561.12. Following the completion of the sale, the insider now directly owns 10,623 shares in the company, valued at approximately $1,725,918.81. The disclosure for this sale can be found here. Insiders have sold a total of 411,255 shares of company stock worth $55,309,981 over the last three months. 15.20% of the stock is currently owned by insiders.

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Moderna by 22.6% during the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after buying an additional 6,248,623 shares during the period. Norges Bank purchased a new stake in Moderna in the 4th quarter worth approximately $347,565,000. The Manufacturers Life Insurance Company lifted its stake in Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after purchasing an additional 1,614,460 shares during the period. Finally, Invesco Ltd. grew its position in shares of Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Recommended Stories

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.